MLTX
MoonLake Immunotherapeutics
Set alert
11.78 USD -0.79 -6.28%
11.71 Day range 12.63
9.55 52-week range 22.16
- YTD
- -10.62%
- 1 year
- +20.08%
- Open
- 12.44
- Prev close
- 12.57
- Mkt cap
- 1.00B
- Vol
- 1.13M
- Avg vol
- 1.69M
- EPS
- -3.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.71
- High
- 12.63
- Forward P/E
- -3.54
- Beta
- 1.08
- Short ratio
- 4.01
- Inst. own
- 87.73%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 12.60
- 200-d avg
- 16.49
- 1y target
- 28.54
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 634.29M
- Trailing P/E
- 0.00
- Forward P/E
- -3.54
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.30
- EPS (TTM)
- -3.83
- Beta
- 1.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -131.86M
- Total cash
- 537.03M
- Total debt
- 101.53M
- Return on equity
- -67.47%
- Shares outstanding
- 85.11M
- Short % of float
- 12.69%
- 50-day average
- 12.60
- 200-day average
- 16.49
Analyst view
Consensus: buy
Buy
Price target (mean) 28.54 +142.3% upside
Now 11.78
- Target (low)
- 6.00
- Target (mean)
- 28.54
- Target (high)
- 50.00
Ratings (0m) 15 11 buy · 2 hold · 2 sell
- Strong buy1
- Buy10
- Hold2
- Sell2
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate -0.78081.
Financials — quick view
MLTX Revenue — quarterly 0
MLTX Net income — quarterly -61.80M
MLTX EPS — quarterly -0.84
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | -0.77 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.90859 | -0.84 | +0.07 | +7.55% |
| May 11, 2026 | Mar 31, 2026 | -0.91 | -0.98 | -0.07 | -7.69% |
| Feb 25, 2026 | Dec 31, 2025 | -0.92 | -0.92 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.89 | -1.10 | -0.21 | -23.60% |
| Aug 5, 2025 | Jun 30, 2025 | -0.73 | -0.87 | -0.14 | -19.18% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 1, 2026 | Leerink Partners | main | Outperform | Outperform |
| Jun 9, 2026 | BTIG | reit | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- moonlaketx.com
News
- What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
- What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday
- HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $50 Price Target
- MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
- HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50
- MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
- MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
- MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
Your note
Sign in to keep a note on MLTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BODENSTEDT MATTHIAS | Chief Financial Officer | Sale | Jun 21, 2026 | 1,115,440 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 30, 2026 | 0 |
| CHEN BIHUA X. | Former | Sale | Sep 29, 2025 | 0 |
| MOUKHEIBIR CATHERINE | Director | Sale | Jul 2, 2025 | 0 |
| REICH KRISTIAN | Officer | Sale | Jul 26, 2026 | 0 |
| SANTOS DA SILVA JORGE | Chief Executive Officer | Sale | Jul 9, 2026 | 2,774,890 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 18.80% | 16,001,284 | 188.50M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.22% | 6,999,025 | 82.45M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.03% | 4,280,624 | 50.43M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 3.95% | 3,365,507 | 39.65M | Jun 29, 2026 |
| Cormorant Asset Management, LP | 3.77% | 3,205,433 | 37.76M | Jun 29, 2026 |
| Jupiter Topco LLC | 3.63% | 3,085,906 | 36.35M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.90% | 1,614,289 | 19.02M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1.08% | 918,586 | 10.82M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.93% | 792,072 | 9.33M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 0.71% | 605,474 | 7.13M | Jun 29, 2026 |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 0.41% | 350,134 | 4.12M | Jun 29, 2026 |
| T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 0.20% | 167,768 | 1.98M | Jun 29, 2026 |